HPVC2016-108 Biopharmaceutical - Infliximab
- Contract Start Date
- 01 Feb 2016
- Contract End Date
- 30 Apr 2020
- Option Periods
- 1 x 2 Years Remaining
For the provision of Biopharmaceutical Infliximab
The Principal Period commenced on 1st of February 2016 and ran until 30th of April 2018.
The Contract Option period of two years has been executed – effective from 1st of May 2018 until 30th of April 2020.
Option Periods Remaining
1 x 2 Years
HPV is now seeking expressions of interest from incumbent contractors with a view to exercise the option for the products currently on contract. If you have any questions regarding this option review event, please contact Maryanne Yang on firstname.lastname@example.org or 9947 3788.
Sales Report Template
(You must be a registered supplier on the HPV website and have logged in to access the link above for the new reporting template.)